Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic acid alone or with bezafibrate in primary biliary cholangitis
2018-002575-17Phase 2Active
- Sponsor
- Intercept Pharmaceuticals
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of obeticholic acid, bezafibrate in primary biliary cholangitis (PBC), sponsored by Intercept Pharmaceuticals. Started Jun 2019; status: active.
02
Drugs
obeticholic acidbezafibrate
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on 2018-002575-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002575-17.